Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Other common side effects may include fatigue, dizziness, bloating, gallstones, heartburn, injection site reactions, hair loss, and low blood sugar (in people with type 2 diabetes)
Phase 3 REDEFINE trials of CagriSema are ongoing as of 2026
These medications usually require a prescription, and insurance often limits coverage to people who meet specific health criteria, like obesity or diabetes
HER2 overexpression or pathway activation is exhibited in about 5% to 20% of CCAs, and 15% to 30% of gallbladder cancer, for which off-label fam-trastuzumab deruxtecan-nxki (Enhertu, for IHC 3+), trastuzumab/pertuzumab (Phesgo) and trastuzumab + tucatinib (Herceptin + Tukysa) are recommended for HER2+ tumors after disease progression
If the bio-betters primary patents expire in 3 years and it has no defensive secondary patent filing program, the NPV of a biosimilar program against that reference looks markedly more attractive
US$ 23.53
US$ 24.49
US$ 22.38
